Tao Guo

机构：Jiangnan University, Shenyang Agricultural University, Kunming Medical University, Third People's Hospital of Chengdu, Wuxi Fourth People's Hospital · ORCID：0000-0001-6055-0985

发表论文 70 篇 · 总被引 3699 次 · h-index 25

代表论文

• Deep learning enables rapid identification of potent DDR1 kinase inhibitors (2019 · Nature Biotechnology · 被引 1564)
• Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor (2019 · Journal of Medicinal Chemistry · 被引 99)
• A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles (2023 · Journal of Nanobiotechnology · 被引 49)
• Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors (2018 · Journal of Medicinal Chemistry · 被引 44)
• Strategies for High-Efficiency Mutation Using the CRISPR/Cas System (2022 · Frontiers in Cell and Developmental Biology · 被引 34)
• Gastrodin Regulates PI3K/AKT-Sirt3 Signaling Pathway and Proinflammatory Mediators in Activated Microglia (2023 · Molecular Neurobiology · 被引 21)